Page last updated: 2024-08-21

isoxazoles and Diabetes Mellitus

isoxazoles has been researched along with Diabetes Mellitus in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19901 (8.33)18.7374
1990's2 (16.67)18.2507
2000's5 (41.67)29.6817
2010's3 (25.00)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Abdelhamid, HN; Abdulkhair, BY; Algethami, FK; Ben Jannet, H; Chrouda, A; Elamin, MR; Saidi, I1
Fujioka, K1
Choi, JW; Jun, HS; Jung, JY; Li, HY; Oh, YS1
Arita, E; Auwerx, J; Horai, Y; Houten, SM; Itoh, H; Mataki, C; Morimoto, K; Sato, H; Schoonjans, K; Sugizaki, T; Tanigawara, Y; Watanabe, M1
Bymaster, FP; Cowley, MA; Gadde, KM; Krishnan, RK; Landbloom, RP; McKinney, AA; Sinnayah, P; Tollefson, GD; Wallingford, NM1
Chong, AS; Foster, P; Guo, Z; Jensik, SC; McChesney, L; Mital, D; Sankary, H; Shen, J; Tian, Y; Williams, JW1
Kadowaki, T1
Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F1
Hasegawa, M; Makino, H; Nishimiya, T; Ochi, M; Onuma, H; Osawa, H; Tang, Y1
Fehr, T; Ochsenbein, AF; Pinschewer, DD; Zinkernagel, RM1
Shinkai, H1
Bonetti, A; D'Antuono, A; Magnati, G; Pugnoli, C; Strata, A; Tirelli, F; Zuliani, U1

Reviews

3 review(s) available for isoxazoles and Diabetes Mellitus

ArticleYear
Current and emerging medications for overweight or obesity in people with comorbidities.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:11

    Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidemias; Epoxy Compounds; Humans; Hypertension; Isoxazoles; Obesity; Overweight; Prediabetic State; Sesquiterpenes; Weight Loss; Zonisamide

2015
[Insulin-sensitizing agents].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:3

    Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones

1999
[The chemical structure and pharmacological properties of a novel isoxazolidinedione insulin sensitizer, JTT-501].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:11

    Topics: Animals; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Neuropathies; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Isoxazoles; Monosaccharide Transport Proteins; Muscle Proteins; Rats; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Transcription Factors

2001

Trials

1 trial(s) available for isoxazoles and Diabetes Mellitus

ArticleYear
[Clinico-pharmacological study of a new oral hypoglycemic agent].
    La Clinica terapeutica, 1978, Apr-30, Volume: 85, Issue:2

    Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Female; Glyburide; Humans; Isoxazoles; Male; Middle Aged; Placebos

1978

Other Studies

8 other study(ies) available for isoxazoles and Diabetes Mellitus

ArticleYear
Trifluoromethylated Flavonoid-Based Isoxazoles as Antidiabetic and Anti-Obesity Agents: Synthesis, In Vitro
    Molecules (Basel, Switzerland), 2021, Aug-27, Volume: 26, Issue:17

    Topics: alpha-Amylases; alpha-Glucosidases; Anti-Obesity Agents; Diabetes Mellitus; Flavonoids; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Isoxazoles; Molecular Docking Simulation; Structure-Activity Relationship

2021
Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
    Kidney international, 2017, Volume: 91, Issue:6

    Topics: Animals; Cell Line; Diabetes Mellitus; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Glycogen Synthase Kinase 3 beta; Isoxazoles; Kidney Cortex; Lysophospholipids; Male; Mice, Inbred C57BL; Phosphoric Diester Hydrolases; Phosphorylation; Propionates; Receptors, Lysophosphatidic Acid; RNA Interference; Signal Transduction; Smad2 Protein; Smad3 Protein; Sterol Regulatory Element Binding Protein 1; Time Factors; Transfection; Transforming Growth Factor beta

2017
Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure.
    The Journal of biological chemistry, 2011, Jul-29, Volume: 286, Issue:30

    Topics: 3T3-L1 Cells; Animals; Bile Acids and Salts; Body Weight; Diabetes Mellitus; Dietary Fats; Energy Metabolism; Isoxazoles; Metabolic Syndrome; Mice; Obesity; Receptors, Cytoplasmic and Nuclear

2011
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:12

    Topics: Animals; Anticonvulsants; Appetite Regulation; Benzodiazepines; Biomarkers; Body Weight; Diabetes Mellitus; Female; Hyperglycemia; Hyperphagia; Hypothalamic Area, Lateral; Intracellular Signaling Peptides and Proteins; Isoxazoles; Neurons; Neuropeptides; Nucleus Accumbens; Obesity; Olanzapine; Orexins; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Gain; Zonisamide

2008
Immunosuppression preventing concordant xenogeneic islet graft rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice.
    Transplantation, 1998, May-27, Volume: 65, Issue:10

    Topics: Animals; Autoimmune Diseases; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Graft Rejection; Immunosuppression Therapy; Immunosuppressive Agents; Islets of Langerhans Transplantation; Isoxazoles; Leflunomide; Mice; Mice, Inbred NOD; Mice, Inbred Strains; Rats; Rats, Sprague-Dawley; Recurrence; Transplantation, Heterologous

1998
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
    British journal of pharmacology, 2000, Volume: 130, Issue:3

    Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chromans; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Neuropathies; Eating; Hypoglycemic Agents; Isoxazoles; Male; Neural Conduction; Obesity; Pancreas; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone

2000
Adipocyte-specific reduction of phosphodiesterase 3B gene expression and its restoration by JTT-501 in the obese, diabetic KKAy mouse.
    European journal of endocrinology, 2001, Volume: 145, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Cyclic Nucleotide Phosphodiesterases, Type 3; Diabetes Mellitus; Diabetes Mellitus, Experimental; Epididymis; Fatty Acids; Female; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Insulin; Insulin Resistance; Isoxazoles; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Triglycerides

2001
Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine.
    Transplantation, 2001, Aug-27, Volume: 72, Issue:4

    Topics: Animals; Antibodies, Viral; Antibody Formation; Autoimmune Diseases; CD8-Positive T-Lymphocytes; Diabetes Mellitus; Dose-Response Relationship, Drug; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocytic choriomeningitis virus; Mice; Mice, Inbred C57BL; Mice, Transgenic; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Uridine; Vesicular stomatitis Indiana virus

2001